CGRP Forum is made possible thanks to support from AbbVie, Lilly, Organon and Pfizer, all of whom have no influence or control of editorial content. More information is available here »
London, UK, 6-9 September 2018
Intravenous eptinezumab reduces migraine prevalence by at least 50% in the first 24 hours after administration and provides sustained levels of response with repeated prophylaxis over 12 months. Data from the PROMISE-1 study, presented by Professor David Dodick, from the Mayo Clinic College of Medicine, Phoenix, Arizona, showed a 55% reduction in migraine day prevalence …
Read more »A novel analysis of Phase 2 erenumab data may help set expectations for the impact of ongoing erenumab 70 mg or 140 mg on monthly migraine days (MMDs) and disability for patients with chronic migraine who respond to prophylaxis. Amongst patients who achieved a > 50% response to erenumab, MMDs were reduced by approximately 12 …
Read more »Migraine reduces overall work productivity by half and places a significant burden on healthcare providers through ER visits, overnight stays and need for brain scans, according to a series of presentations from the My Migraine Voice survey. The international online survey of 11,266 people with a mean 11.6 years of migraine and at least 4 …
Read more »In patients with chronic migraine, botulinum toxin type A reduces migraine frequency by three days/month and migraine severity by 30%, according to results of a systematic Cochrane review of botulinum toxins in adults with migraine. These findings are based on analysis of data from 4192 patients in 28 trials reported in 90 articles. All larger …
Read more »Galcanezumab is as effective in menstrual migraine as in other forms of the disease, according to post-hoc analyses from the EVOLVE-1 and EVOLVE-2 studies in episodic migraine and the REGAIN study in chronic migraine (Tables 1 and 2). Dr Sheena Aurora, from Eli Lilly, Indianapolis, USA, explained that menstrual migraine is more severe than non-menstrual …
Read more »Chocolate is associated with migraine in only about one in 10 people with migraine and, in almost the same proportion, it appears to protect, according to new data. In a digital study of 774 people with migraine who answered questions about their chocolate intake and headaches over a 90-day period, chocolate was found to be …
Read more »
This program is funded in part via an independent educational grant from AbbVie.
Organon has provided sponsorship towards this independent resource. Organon has had no editorial input or control over content, nor opportunity to influence.
Financial support was provided as GMG Knowledge Gap Grant from Pfizer Inc, Pfizer have provided only financial support and had no input into the content provided.
